The company has faced its share of issues in the last year – Lilly took a $150 million hit in November after its Alzheimer’s drug failed in a clinical trial and this month, the FDA rejected its rheumatoid arthritis drug. But the company’s diabetes therapies, such as Trulicity and Humalog, helped to propel the company to an adjusted quarterly profit that beat expectations on The Street.
“We are encouraged by another solid performance from Lilly’s overall diabetes franchise,” Leerink Partners analyst Seamus Fernandez said in a note, according to Reuters.
Get the full story at our sister site, Drug Delivery Business News.
The post Eli Lilly’s diabetes drugs boost Q1 revenue, earnings appeared first on MassDevice.
from MassDevice http://ift.tt/2oGqF5q
Cap comentari:
Publica un comentari a l'entrada